Objectives and methodology of the COBRA-SIJ trial
The COBRA-SIJ trial (Conventional or Bipolar Radiofrequency Ablation for the Treatment of Sacroiliac Joint Pain) is a double-blind, randomized, comparative study designed to evaluate radiofrequency ablation strategies targeting the posterior sacral network in patients with sacroiliac joint complex pain. The sacroiliac joint complex is a diarthrodial, synovial joint with a posterior ligamentous network that receives anterior innervation from the lumbosacral plexus and posterior sensory innervation via the posterior sacral network, which is composed primarily of the lateral branches of the S1–S3 posterior rami, with variable contributions from the S4 lateral branch and the L5 dorsal ramus. Pain signals from this complex can be interrupted using image-guided percutaneous radiofrequency ablation of the posterior sacral network, which has been associated with reductions in pain and disability in appropriately selected patients.
The primary purpose of the COBRA-SIJ study is to compare the effectiveness of a bipolar palisade strip-lesion technique (Nimbus sacroiliac joint radiofrequency ablation, N-SIJRFA) with a conventional monopolar periforaminal technique (C-SIJRFA) for posterior sacral network ablation in sacroiliac joint complex pain. Cadaveric work has suggested that bipolar strip lesions can achieve substantially higher rates of neural capture of the posterior sacral network than conventional periforaminal monopolar lesions, which may translate into improved clinical outcomes. The central hypothesis of the trial is that N-SIJRFA will be more effective than C-SIJRFA in improving pain and function at multiple follow-up time points, including 3, 6, 12, 18, and 24 months.
The study is structured as a double-blinded randomized controlled trial in which adult participants aged 18–90 years with chronic low back pain attributable to the sacroiliac joint complex are randomized to receive either N-SIJRFA or C-SIJRFA. Participants must have at least three months of low back pain, have failed at least three months of conservative treatment, and report a 7-day average Numeric Pain Rating Scale (NPRS) score of at least 4/10 at baseline. Diagnosis of sacroiliac joint complex pain is based on clinical examination, imaging, and response to fluoroscopically guided intra-articular sacroiliac joint injections and/or posterior sacral network blocks, with eligibility requiring at least 50% pain relief following these diagnostic or prognostic interventions.
The trial incorporates multiple specific aims that extend beyond pain intensity to include functional and quality-of-life outcomes. Primary and key secondary endpoints include the proportion of participants achieving more than 50% pain relief on the NPRS, the proportion achieving at least a 15-point reduction on the Oswestry Disability Index (ODI), and the proportion with clinically significant improvement in EuroQol 5 Dimensions (EQ-5D) scores, defined as a change of at least 0.03. Additional aims include evaluating patient global impression of change, pain-related sleep disturbance measured by the Pain and Sleep Questionnaire (PSQ-3), procedure time and fluoroscopy exposure, adverse events, and subsequent interventional utilization such as repeat radiofrequency ablation, sacroiliac joint injections, or sacroiliac joint fusion.
Methodologically, the COBRA-SIJ protocol standardizes both diagnostic and therapeutic steps to minimize confounding. Prognostic posterior sacral network blocks and diagnostic intra-articular sacroiliac joint injections are performed under fluoroscopic guidance, and pain response is documented using structured pain diaries with categorical relief levels. Randomization is followed by a standardized radiofrequency ablation procedure in which both groups receive an L5 dorsal ramus lesion at the junction of the sacral ala and S1 superior articular process to control for potential L5/S1 facet-mediated pain, while the posterior sacral network from S1 to S3 is targeted using either a bipolar palisade configuration (Nimbus) or a conventional periforaminal monopolar technique. The double-blind design, with participants unaware of group allocation, is intended to reduce bias in patient-reported outcomes.
Key clinical results and statistical outcomes
The COBRA-SIJ materials specify a comprehensive set of planned clinical and statistical outcomes, reflecting the multifactorial impact of sacroiliac joint complex pain and its treatment. The primary outcome is the proportion of participants achieving more than 50% pain relief on the Numeric Pain Rating Scale following N-SIJRFA versus C-SIJRFA at prespecified follow-up intervals up to 24 months. This threshold aligns with prior systematic reviews of posterior sacral network ablation, which have reported that 32–89% of patients may achieve at least 50% pain relief for six months after such procedures, highlighting the need to clarify the contribution of technique and lesion geometry to clinical response.
Functional improvement is captured primarily through the Oswestry Disability Index, with a 15-point or greater reduction defined as a clinically meaningful change. Health-related quality of life is assessed using the EQ-5D instrument, with a change of at least 0.03 considered clinically significant. The protocol also includes the Patient Global Impression of Change (PGIC) to categorize participants as improved or much improved, providing a global patient-centered measure that complements numeric pain and disability scores. Pain-related sleep disturbance is evaluated using the PSQ-3, recognizing the impact of sacroiliac joint complex pain on sleep and overall functioning.
Beyond these primary and secondary endpoints, the COBRA-SIJ trial is designed to explore several clinically relevant sub-analyses. One objective is to compare success rates for pain, function, and satisfaction among participants who experience varying degrees of pain relief (50% or greater, 80% or greater, and complete relief) after prognostic posterior sacral network blocks or intra-articular sacroiliac joint injections. This stratification is intended to clarify how the magnitude of response to diagnostic or prognostic interventions relates to subsequent outcomes after neuroablation. Another objective is to document procedure-related metrics, including total procedure time, fluoroscopy time, absorbed radiation dose, and the presence of trainees, which may influence efficiency and resource utilization in clinical practice.
Safety and longer-term care trajectories are integral components of the outcome framework. The protocol mandates systematic reporting of adverse events, including cardiopulmonary compromise, neurologic deficits, neuritis, vasovagal syncope, and infection, as well as post-procedural pain and procedural NPRS scores. It also tracks subsequent interventional utilization, such as repeat Nimbus or conventional sacroiliac joint radiofrequency ablation, sacroiliac joint injections, and sacroiliac joint fusion, to characterize durability of benefit and the need for additional procedures over time. While the protocol and related documents outline these planned analyses and endpoints, they emphasize that the study is intended to fill a major knowledge gap regarding the impact of complete posterior sacral network ablation using a bipolar palisade technique on clinical outcomes, with the potential to influence future treatment paradigms once results are fully analyzed.
The statistical interpretation of lesion geometry and neural capture from prior anatomical and cadaveric work provides important context for the expected clinical outcomes. Cadaveric comparisons have indicated that bipolar strip lesions can achieve markedly higher rates of posterior sacral network neural capture than conventional periforaminal monopolar lesions, with some estimates of complete neural capture for conventional techniques being as low as 12.5%. These anatomical data, combined with systematic review findings of heterogeneous success rates across different radiofrequency techniques, underpin the hypothesis that lesion size and configuration are critical determinants of pain relief and functional improvement in sacroiliac joint complex pain. The COBRA-SIJ trial outcome structure is therefore explicitly aligned with testing whether a bipolar palisade approach can translate these anatomical advantages into superior clinical and patient-reported outcomes.
Impact on current SIJ treatment protocols
The COBRA-SIJ protocol is framed against a background of substantial variability in sacroiliac joint radiofrequency ablation techniques and outcomes. Prior systematic reviews have documented wide ranges in treatment success, with 32–89% of patients achieving at least 50% pain relief for six months and 11–44% achieving complete relief over the same period following posterior sacral network ablation. This heterogeneity has been attributed in part to differences in lesion size, configuration, and targeting strategies, including conventional monopolar periforaminal approaches, cooled monopolar lesions, and multi-electrode continuous lesions. The COBRA-SIJ study directly addresses this variability by comparing a bipolar palisade strip-lesion technique with a widely used conventional monopolar periforaminal method within a rigorous randomized, double-blind framework.
The protocol emphasizes that complete or near-complete capture of the posterior sacral network is a key conceptual goal of sacroiliac joint neuroablation. Cadaveric work has suggested that bipolar strip lesions along the sacral lateral crest can achieve substantially higher rates of neural capture than conventional periforaminal monopolar lesions, which may capture only a small fraction of the posterior sacral network. In parallel, broader evidence syntheses on radiofrequency neurotomy for sacroiliac joint pain have highlighted that the use of bipolar or cooled radiofrequency techniques, which generate larger lesions, is considered ideal to ensure capture of the lateral branches, whereas monopolar techniques may require multiple passes or periforaminal strategies to approximate similar lesion coverage. By standardizing and directly comparing these approaches, COBRA-SIJ is positioned to inform whether larger, continuous strip lesions should be preferentially incorporated into treatment protocols.
Current sacroiliac joint treatment pathways typically progress from conservative measures, such as physical therapy and non-steroidal anti-inflammatory drugs, to image-guided injections and, in selected cases, radiofrequency neuroablation or fusion. Within this framework, the COBRA-SIJ study reinforces the role of prognostic posterior sacral network blocks and diagnostic intra-articular sacroiliac joint injections as standard components of patient selection for neuroablation. The requirement for at least 50% pain relief following these diagnostic or prognostic procedures aligns with broader recommendations that emphasize diagnostic blocks as a critical step before proceeding to lateral sacral branch radiofrequency neurotomy. As such, the trial supports a structured, stepwise approach in which neuroablation is reserved for patients with well-characterized sacroiliac joint complex pain and demonstrable block responsiveness.
The anticipated impact of COBRA-SIJ on treatment protocols extends to procedural standardization and safety monitoring. The protocol specifies detailed technical parameters for both Nimbus and conventional techniques, including lesion temperatures and durations (85°C for 180 seconds for bipolar sites and 80°C for 90 seconds for the monopolar L5 dorsal ramus lesion), fluoroscopic targeting strategies, and systematic documentation of adverse events and radiation exposure. These elements provide a template for reproducible practice that can be adopted or adapted in clinical settings. Moreover, the consent materials explicitly outline expected side effects and potential complications of sacroiliac joint radiofrequency ablation, such as temporary pain, neuritis, minor bleeding, infection, and rare motor nerve damage, reinforcing the need for careful risk–benefit assessment and patient counseling when integrating neuroablation into sacroiliac joint treatment algorithms.
The COBRA-SIJ study is designed to capture downstream interventional utilization, including repeat radiofrequency ablation and sacroiliac joint fusion, which are important markers of long-term effectiveness and treatment sequencing. In the broader context of radiofrequency neurotomy literature, sacral lateral branch neurotomy is considered a viable option for posterior sacral ligament and joint pain following a positive response to diagnostic blocks, with evidence supporting the clinical efficacy of unipolar, bipolar, cooled, and pulsed radiofrequency techniques, albeit with limitations in study quality and heterogeneity. The COBRA-SIJ trial contributes to this evolving evidence base by directly comparing two commonly used techniques and by embedding its findings within a structured, block-based selection and follow-up framework that can inform contemporary sacroiliac joint treatment protocols.
Translating research into clinical workflows
The COBRA-SIJ protocol provides a detailed, stepwise framework that can be mapped onto routine clinical workflows for managing sacroiliac joint complex pain. Initial evaluation emphasizes a thorough clinical assessment, including history, physical examination, and imaging, to identify low back pain attributable to the sacroiliac joint complex, which may account for a substantial proportion of chronic low back pain presentations. Once sacroiliac joint complex pain is suspected, conservative measures such as physical therapy and pharmacologic management are pursued for at least three months before interventional options are considered, reflecting standard practice patterns.
For patients who remain symptomatic despite conservative care, the COBRA-SIJ workflow incorporates fluoroscopically guided diagnostic and prognostic procedures as gatekeepers to neuroablation. These include intra-articular sacroiliac joint injections with local anesthetic and posterior sacral network blocks, with eligibility for radiofrequency ablation contingent on achieving at least 50% pain relief as documented in a structured pain diary. This approach is consistent with broader recommendations that emphasize the importance of diagnostic blocks of the lateral sacral branches before proceeding to radiofrequency neurotomy, even in patients who have previously undergone sacroiliac joint injections. Incorporating such block-based selection into clinical workflows can help identify patients most likely to benefit from posterior sacral network ablation and reduce unnecessary procedures.
The procedural aspects of COBRA-SIJ can also be translated into standardized operating room or procedure suite protocols. For both Nimbus and conventional techniques, the protocol specifies patient positioning, fluoroscopic views, electrode placement, lesion parameters, and safety checks, including confirmation of electrode position in anteroposterior and lateral projections and the use of local anesthetic prior to lesioning. For the conventional group, a periforaminal electrode position is used to target the lateral branches from S1 to S3, with specific analog clock positions relative to the posterior sacral foramina, while the Nimbus group employs a series of parallel electrodes along the sacral lateral crest to create a continuous bipolar strip lesion. These detailed technical descriptions can be incorporated into procedural checklists, training curricula, and quality assurance processes to enhance consistency and safety in clinical practice.
Post-procedural follow-up in the COBRA-SIJ study is structured around serial assessments of pain, function, quality of life, sleep, and medication use at multiple time points up to 24 months. Data collection includes NPRS scores, ODI, EQ-5D, PSQ-3, opioid consumption, and patient global impression of change, as well as documentation of adverse events and subsequent interventions. This comprehensive follow-up framework can inform clinical workflows by highlighting the importance of longitudinal monitoring after sacroiliac joint neuroablation, not only to evaluate efficacy but also to detect complications, adjust analgesic regimens, and determine the need for repeat procedures or alternative interventions such as sacroiliac joint fusion.
Integrating COBRA-SIJ concepts into practice also involves aligning patient communication and consent processes with the study risk–benefit framing. The consent materials describe both Nimbus and conventional sacroiliac joint radiofrequency ablation as standard-of-care procedures, outline potential side effects and complications, and emphasize that participation involves randomization between two accepted techniques whose comparative effectiveness is under investigation. Clinicians can adapt this language to routine care by clearly explaining the rationale for posterior sacral network ablation, the role of diagnostic blocks, the expected magnitude and duration of pain relief based on existing evidence, and the potential need for future interventions. In this way, the COBRA-SIJ study serves not only as a research protocol but also as a model for structured, evidence-informed clinical workflows in sacroiliac joint complex pain management.
Patient eligibility and stratification
The COBRA-SIJ trial defines a detailed set of inclusion and exclusion criteria that can guide patient eligibility and stratification in clinical practice. Eligible participants are adults aged 18–90 years with at least three months of low back pain that has not responded to a minimum of three months of conservative treatment, including modalities such as physical therapy and pharmacologic management. Baseline pain intensity must be at least 4/10 on a 7-day average Numeric Pain Rating Scale, ensuring that enrolled patients have clinically significant symptoms. Pain must be attributable to the sacroiliac joint complex based on physical examination, imaging, and response to diagnostic or prognostic injections, reflecting a multimodal diagnostic approach.
A central eligibility requirement is a robust response to image-guided diagnostic or prognostic procedures. Participants must demonstrate at least 50% pain relief following either both a fluoroscopically guided intra-articular sacroiliac joint injection with local anesthetic and a fluoroscopically guided posterior sacral network block, or dual posterior sacral network blocks. Pain diaries with categorical relief levels are used to document response, although duration of relief is not used for eligibility decisions, as it has been shown to only marginally improve diagnostic confidence. This block-based selection strategy aligns with broader recommendations that emphasize diagnostic lateral sacral branch blocks, with a suggested threshold of at least 50% pain reduction before proceeding to radiofrequency neurotomy.
Exclusion criteria in COBRA-SIJ are designed to avoid confounding pain generators, technical limitations, and safety concerns. Patients with a history of sacroiliac joint fusion, prior sacroiliac joint radiofrequency ablation, symptomatic hip osteoarthritis, active lumbar radicular pain, or evidence of hardware loosening after lumbar or lumbosacral fusion are excluded, as these conditions may contribute to pain that is not primarily mediated by the posterior sacral network. Additional exclusions include the presence of pacemakers or neurostimulators, chronic widespread pain or somatoform disorders such as fibromyalgia, high-dose opioid use exceeding 50 mg morphine-equivalent per day, and active or recently treated bacterial infection, reflecting standard precautions for interventional pain procedures.
The protocol also specifies extensive baseline data collection that can support stratification and outcome interpretation. Demographic variables, pain characteristics, comorbidities, psychosocial factors, and baseline functional and quality-of-life measures are systematically recorded. Procedural and radiographic data, including whether the procedure is unilateral or bilateral, use of sedation, presence of trainees, procedure time, absorbed radiation dose, and pelvic incidence angle, are also captured. In clinical practice, similar data collection can facilitate risk stratification, identification of subgroups with differential response to neuroablation, and more nuanced shared decision-making regarding sacroiliac joint interventions.
Taken together, the COBRA-SIJ eligibility and stratification framework underscores the importance of careful patient selection for sacroiliac joint neuroablation. By requiring a clear diagnostic signal from blocks, excluding competing pain generators and high-risk conditions, and documenting a broad range of baseline characteristics, the study seeks to isolate the effect of posterior sacral network ablation on sacroiliac joint complex pain. Clinicians can draw on this framework to refine their own criteria for offering radiofrequency neurotomy, ensuring that candidates have well-characterized sacroiliac joint complex pain, adequate response to diagnostic interventions, and an acceptable risk profile for interventional procedures.
Future perspectives in neuroablation
The COBRA-SIJ study is situated within a broader evolution of neuroablation techniques for sacroiliac joint complex pain, in which lesion geometry, targeting strategies, and energy delivery modalities are being refined to improve efficacy and safety. Anatomical and cadaveric studies have demonstrated that the posterior sacral network is composed of lateral branches from S1 to S3, with variable contributions from S4 and the L5 dorsal ramus, and that bipolar strip lesions along the sacral lateral crest can achieve higher rates of neural capture than conventional periforaminal monopolar lesions. These findings have motivated the development of techniques such as the Nimbus bipolar palisade approach evaluated in COBRA-SIJ, as well as other multi-electrode and cooled radiofrequency systems designed to create larger, more contiguous lesions.
Evidence syntheses on radiofrequency neurotomy for sacroiliac joint pain indicate that unipolar, bipolar, cooled, and pulsed radiofrequency techniques can all provide clinical benefit, but highlight substantial heterogeneity in study designs, patient selection, lesion parameters, and follow-up durations. Many existing studies have relied on intra-articular sacroiliac joint injections for patient selection, whereas posterior sacral network blocks may be more prognostic for outcomes after lateral sacral branch neurotomy. The COBRA-SIJ trial, with its emphasis on block-based selection and direct comparison of bipolar and conventional techniques, addresses several of these gaps and may inform future research directions, including standardized diagnostic pathways, optimized lesion configurations, and comparative effectiveness studies across different radiofrequency modalities.
Future perspectives in sacroiliac joint neuroablation also involve refining procedural targets and potentially revisiting the role of specific nerve contributions. Anatomical work has shown that the L5 dorsal ramus may contribute to the posterior sacral network by traveling caudally to the level of S1, and the COBRA-SIJ protocol includes a monopolar lesion at the L5 dorsal ramus in both treatment arms to control for possible L5/S1 facet-mediated pain. At the same time, other clinical studies of ultrasound-guided sacroiliac joint radiofrequency ablation have omitted L5 dorsal ramus ablation and still reported outcomes comparable to fluoroscopy-guided techniques that include L5, suggesting that the necessity of L5 targeting may vary depending on technique and patient anatomy. These observations point toward a future in which neuroablation protocols are increasingly tailored to individual anatomical patterns and prior treatment history.
There is a recognized need for higher-quality, standardized research to guide neuroablation practice. Reviews of radiofrequency neurotomy for sacroiliac joint pain have identified heterogeneity in diagnostic criteria, lesion parameters, and outcome measures as major limitations, and have called for further studies on both diagnostic sacral nerve blocks and neurotomy itself. The COBRA-SIJ trial responds to this need by specifying rigorous inclusion criteria, standardized block protocols, detailed procedural descriptions, and a comprehensive set of patient-centered outcomes with long-term follow-up. As results from COBRA-SIJ and related studies become available, they are likely to inform consensus statements, refine indications for sacral lateral branch neurotomy, and support the development of more uniform practice standards in sacroiliac joint complex pain management.
In summary, future directions in neuroablation for sacroiliac joint complex pain will likely be shaped by a convergence of anatomical insights, technological advances in lesion creation, and methodologically robust clinical trials such as COBRA-SIJ. Emphasis on complete or near-complete posterior sacral network capture, block-based patient selection, and standardized outcome assessment provides a framework for ongoing innovation and evaluation. As the evidence base matures, clinicians will be better equipped to integrate neuroablation into multimodal treatment strategies for sacroiliac joint complex pain, balancing efficacy, safety, and resource utilization in diverse patient populations.
Sources (Bibliography)
- Conger A, McCormick Z, Kendall R, Wagner G, Burnham T. Conventional or Bipolar Radiofrequency Ablation for the Treatment of Sacroiliac Joint Pain? The COBRA-SIJ study, a Double-blind, Randomized, Comparative Trial. Protocol Version 3.0, 03JAN2023.
- Conger A. Conventional or Bipolar Radiofrequency Ablation for the Treatment of Sacroiliac Joint Pain? The COBRA-SIJ study, a Double-blinded, Randomized, Comparative Trial. Clinical Trial Agreement, 2021.
- Conger A. Conventional or Bipolar Radiofrequency Ablation for the Treatment of Sacroiliac Joint Pain. The COBRA-SIJ study, a Double-blinded, Randomized, Comparative Trial. Consent and Authorization Document, Version 2, 14SEP2022.
- Lee et al. Latest Evidence Based Application for Radiofrequency Neurotomy. Journal of Pain Research, 2021.
- Wright R, Allen J, Craft R, Holley K. Radiofrequency Ablation Using a Novel Multitined Electrode. 2012.
- Comparisons of Lesion Volumes and Shapes Produced by a Radiofrequency System with a Cooled, Protruding, or Monopolar Probe, 2017.